In summary, we identified the important role of S1PR2/3 in fatty liver injury and demonstrated that S1PR2/3 blockade inhibits liver injury in vivo, strongly suggesting S1PR2/3 might serve as therapeutic targets for fatty liver injury. This evidence concerns the gene S1PR2 and fatty liver disease.